Michael J.  Harrington net worth and biography

Michael Harrington Biography and Net Worth

Mike Harrington is senior vice president and general counsel for Eli Lilly and Company.

Since joining Lilly in 1991 as an attorney in product liability litigation, Mike has served in a number of other business and legal positions, including managing director of the New Zealand affiliate and as associate general counsel for Lilly’s operations inthe Asia-Pacific region. Mike most recently held the role of vice president and deputy general counsel of global pharmaceutical operations. In this capacity, he was responsible for legal issues related to Lilly’s give global business units.

Before joining Lilly, Mike was a litigator at the law firm of Baker & Daniels in Indianapolis.  Mike earned a bachelor’s degree in English from Albion College and a law degree from the Columbia University School of Law. Mike currently serves as the board chair for the Indiana Repertory Theatre and the co-chair of the Civil Justice Reform Group (CJRG). He is also a member of the board of trustees and executive committee of Albion College.

What is Michael J. Harrington's net worth?

The estimated net worth of Michael J. Harrington is at least $29.04 million as of December 6th, 2024. Mr. Harrington owns 37,500 shares of Eli Lilly and Company stock worth more than $29,043,750 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Harrington may own. Learn More about Michael J. Harrington's net worth.

How do I contact Michael J. Harrington?

The corporate mailing address for Mr. Harrington and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Michael J. Harrington's contact information.

Has Michael J. Harrington been buying or selling shares of Eli Lilly and Company?

Michael J. Harrington has not been actively trading shares of Eli Lilly and Company during the last ninety days. Most recently, Michael J. Harrington sold 16,000 shares of the business's stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $116.72, for a transaction totalling $1,867,520.00. Following the completion of the sale, the vice president now directly owns 110,300 shares of the company's stock, valued at $12,874,216. Learn More on Michael J. Harrington's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 11/8/2024.

Michael J. Harrington Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2019Sell16,000$116.72$1,867,520.00110,300View SEC Filing Icon  
6/9/2017Sell22,833$79.97$1,825,955.0162,056View SEC Filing Icon  
See Full Table

Michael J. Harrington Buying and Selling Activity at Eli Lilly and Company

This chart shows Michael J Harrington's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $764.71
Low: $762.50
High: $779.00

50 Day Range

MA: $828.39
Low: $727.57
High: $932.06

2 Week Range

Now: $764.71
Low: $567.02
High: $972.53

Volume

3,303,963 shs

Average Volume

3,209,608 shs

Market Capitalization

$725.95 billion

P/E Ratio

82.67

Dividend Yield

0.66%

Beta

0.41